Evidence map›Paper›PMID 42687863›Full record

ArticleResearch square2026

Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden.

Madeleine Benguigui, Abby Lockwood, Rochani Rajendram, Turkan Gizer, Edward Carter, Eleni Maniati, Pedro Casado, Vinothini Rajeeve, Gilbert Fruhwirth, Cameron Lang and 4 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Madeleine BenguiguiBarts Cancer Institute.
Abby LockwoodBarts Cancer Institute.
Rochani RajendramBarts Cancer Institute.
Turkan GizerBarts Cancer Institute.
Edward CarterUniversity of Bath.
Eleni ManiatiBats Cancer Institute.
Pedro CasadoInstitute of Cancer, Queen Mary University of London.ORCID 0000-0002-4207-9349
Vinothini RajeeveBarts Cancer Institute - Queen Mary University of London.ORCID 0000-0002-6361-4291
Gilbert FruhwirthKing's College London.ORCID 0000-0002-1438-2674
Cameron LangComprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London.
Juan Pedro Martinez-BarberaUniversity College London.ORCID 0000-0002-5292-7276
Scott HastonUniversity College London.
Kairbaan Hodivala-DilkeBarts Cancer Institute.
Ana Rita PedrosaBarts Cancer Institute.ORCID 0000-0002-4421-6968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum-based chemotherapy is widely used to treat non-small cell lung cancer: however, intrathoracic metastasis remains a major clinical challenge associated with increased morbidity. While chemotherapy is generally viewed as acting directly on tumour cells, it can also reprogramme the tumour microenvironment, including vascular endothelial cells. Here, we identify endothelial cell focal adhesion kinase (FAK) as a regulator of cisplatin-induced vascular stress responses that promote metastatic seeding in the lung. Using inducible endothelial cell-specific FAK loss- and endothelial cell-specific kinase-dead mouse models, we show that endothelial cell FAK is required for cisplatin-enhanced lung metastasis. In the pre-metastatic lung, cisplatin induces endothelial cell DNA damage and FAK-dependent transcriptional reprogramming enriched for p53-responsive, stress-adaptive, and senescence-associated genes. Cisplatin treatment also promotes an endothelial cell FAK-dependent secretory and adhesive state increasing tumour cell binding and metastasis seeding in the lung. Mechanistically, cisplatin triggers a transient nuclear accumulation of FAK, where kinase activity supports early ATM signaling and DNA repair. Overall, our data indicate that targeting endothelial cell FAK suppresses these responses and reduces cisplatin-induced lung metastasis.

Indexed as

cisplatinendothelial cellsfocal adhesion kinasemetastasissenescence

Identifiers

PMID42687863
PMCPMC13532713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.